Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis

BACKGROUND: Biological disease-modifying antirheumatic drugs (bDMARDs) are recommended for rheumatoid arthritis (RA), but older patients reportedly experience more adverse events (AEs) and show variable treatment response. The objective of this study was to evaluate AEs and effectiveness of bDMARDs...

Descrición completa

Detalles Bibliográficos
Autores principales: Akter, Ripa, Maksymowych, Walter P., Martin, M. Liam, Hogan, David B.
Formato: Online Artigo Texto
Idioma:English
Publicado: Canadian Geriatrics Society 2020
Materias:
Original Research
Acceso en liña:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259924/
https://www.ncbi.nlm.nih.gov/pubmed/32494334
http://dx.doi.org/10.5770/cgj.23.393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259924/
https://www.ncbi.nlm.nih.gov/pubmed/32494334
http://dx.doi.org/10.5770/cgj.23.393

Títulos similares